Project description:This laboratory focuses on selectin mediated recruitment during adoptive immunotherapy for metastatic cancer. This study seeks to determine changes in the expression levels of Fucosyltransferases, Selectins, and cytokines in normal and inflamed mouse skin, melanoma tumor tissue of different sizes, and tumor cells grown in culture. Since the ability to treat the tumor effectively is directly related to the size of the tumor, differences in glyco-expression patterns may be of interest. In this study, five groups were hybridized and analyzed using the GLYCOv2 array. Each group was analyzed in triplicate. The groups were: Normal mouse skin, normal mouse skin inflamed by treatment with Oxazolone, B16-OVA melanoma tissue from 6 day tumors, B16-OVA melanoma tissue from 11 day tumors, and B16-OVA grown in cell culture.
Project description:Compared to CAR.CD19 T cells, we found that CAR.CD19 NKTs showed superior control of tumor growth in the B16-OVA-hCD19 melanoma model without evident toxicity. To investigate whetehr CAR.CD19 NKTs could affect the TME in the tumor. We used the single RNA seq to test the TME cell populations in the B16-OVA-hCD19 model between CAR.CD19 NKTs and CAR.CD19 Ts.
Project description:We previously showed that transgenic enhancement of histamine production in B16-F10 melanomas strongly supports tumor growth in C57Bl/6 mice (Cancer Res, 2005 Pos et al.). In this array experiment, gene expression profiles of transgenic mouse melanomas, secreting different amounts of histamine, were compared by whole genome microarrays. Experiment Overall Design: By modifying the levels of L-histidine decarboxylase (HDC), the sole enzyme responsible for histamine production, we introduced three novel variants of the B16-F10 mouse melanoma cell line, displaying diminished (B16-F10 HDC-A), unmodified (B16-F10 HDC-M) or enhanced (B16-F10 HDC-S) capacities to produce and secrete histamine. Experiment Overall Design: In this experiment, B16-F10 HDC-A, HDC-M, and HDC-S experimental mouse melanomas were compared by analyzing 6-6 tumors in each group. Experiment Overall Design: In order to reduce the amount of arrays required, equal amounts of randomly chosen RNA sample pairs were pooled in each group, thus, at the end, each group consisted of 3 pooled tumor samples. All samples were biological replicates, no technical replicates or dye swapping were done. Experiment Overall Design: Gene expression patterns of the three tumor groups were compared indirectly, via a common reference samplei n a two-color array design. Arrays shown here represent gene expression patterns of individual tumor samples compared to the reference sample.
Project description:This study investigated how the depletion of natural killer (NK) cells in mice treated with a combined PD-1/CTLA-4 blockade affects the molecular profiles of intracranial tumors in a two-site B16-OVA melanoma brain metastases model. This model contains concomitant intracranial and extracranial tumors, to mimic the presence of extracranial metastases in melanoma patients with brain metastases, and intracranial responses to the combined PD-1/CTLA-4 blockade that are observed in the clinic can be reproduced in this model.
Project description:To establish cancer cells escaping from host immunity, we used murine B16 melanoma cell line expressing ovalbumin (B16OVA) and inoculated into mice immunized with OVA. Using this model, we established cell lines after the in vivo passage through distinct immunological condition. B16OVA tumor exposed to OVA-specific CD8+ T cell immunity in OVA-immunized B6 mice were isolated and established five variants (IMM1, 2, 8). For comparison, B16OVA tumors from non-immunized naïve B6 mice or OVA-immunized IFN-gamma-deficient mice were also isolated and established four variants, namely NIMM (1, 3, 4) cell lines or GKO-IMM (1, 2, 3) cell lines, respectively.
